Literature DB >> 18988869

Going with the flow, and beyond, in myeloma.

Bart Barlogie1, Joshua Epstein, John D Shaughnessy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18988869      PMCID： PMC2582002          DOI： 10.1182/blood-2008-08-175026

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Making progress in treating multiple myeloma with total therapies: issue of complete remission and more.

Authors:  B Barlogie; F van Rhee; J D Shaughnessy; E Anaissie; J Crowley
Journal:  Leukemia       Date:  2008-02-28       Impact factor: 11.528

2.  Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma.

Authors:  M Cavo; C Terragna; G Martinelli; S Ronconi; E Zamagni; P Tosi; R M Lemoli; M Benni; G Pagliani; G Bandini; S Tura
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

3.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

4.  Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.

Authors:  Ronald Walker; Bart Barlogie; Jeffrey Haessler; Guido Tricot; Elias Anaissie; John D Shaughnessy; Joshua Epstein; Rudy van Hemert; Eren Erdem; Antje Hoering; John Crowley; Ernest Ferris; Klaus Hollmig; Frits van Rhee; Maurizio Zangari; Mauricio Pineda-Roman; Abid Mohiuddin; Shmuel Yaccoby; Jeffrey Sawyer; Edgardo J Angtuaco
Journal:  J Clin Oncol       Date:  2007-02-12       Impact factor: 44.544

Review 5.  Role of autologous stem-cell transplantation in multiple myeloma.

Authors:  Michel Attal; Jean-Luc Harousseau
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020

6.  Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

Authors:  Bart Barlogie; Guido Tricot; Elias Anaissie; John Shaughnessy; Erik Rasmussen; Frits van Rhee; Athanasios Fassas; Maurizio Zangari; Klaus Hollmig; Mauricio Pineda-Roman; Choon Lee; Giampaolo Talamo; Raymond Thertulien; Elias Kiwan; Somashekar Krishna; Michele Fox; John Crowley
Journal:  N Engl J Med       Date:  2006-03-09       Impact factor: 91.245

7.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Authors:  Erming Tian; Fenghuang Zhan; Ronald Walker; Erik Rasmussen; Yupo Ma; Bart Barlogie; John D Shaughnessy
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

Review 8.  New drugs for myeloma.

Authors:  Paul G Richardson; Constantine Mitsiades; Robert Schlossman; Nikhil Munshi; Kenneth Anderson
Journal:  Oncologist       Date:  2007-06
  8 in total
  2 in total

1.  Curing myeloma at last: defining criteria and providing the evidence.

Authors:  Bart Barlogie; Alan Mitchell; Frits van Rhee; Joshua Epstein; Gareth J Morgan; John Crowley
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

2.  Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

Authors:  Antje Hoering; John Crowley; John D Shaughnessy; Klaus Hollmig; Yazan Alsayed; Jackie Szymonifka; Sarah Waheed; Bijay Nair; Frits van Rhee; Elias Anaissie; Bart Barlogie
Journal:  Blood       Date:  2009-06-10       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.